{"groups":[{"description":"One Bupropion 150 mg XL capsule by mouth (PO) in a.m. daily for one week; one Bupropion 150 mg XL capsule and one placebo capsule PO in a.m. daily for 8 weeks; one placebo capsule daily PO in a.m. for one 1 week (titration off).","id":"FG000","title":"Bupropion 150 mg"},{"description":"One Bupropion 150 mg XL capsule PO in a.m. daily for one week; two Bupropion 150 mg XL capsules PO in a.m. daily for 8 weeks (300 mg target dose); one Bupropion 150 mg XL capsule PO in a.m. daily for 1 week (titration off)","id":"FG001","title":"Bupropion 300 mg"},{"description":"One placebo capsule PO in a.m. daily for 1 week; two placebo capsules PO in a.m. daily for 8 weeks; one placebo capsule PO in a.m. daily for 1 week (titration off)","id":"FG002","title":"Placebo"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"79"},{"groupId":"FG001","numSubjects":"74"},{"groupId":"FG002","numSubjects":"77"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"79"},{"groupId":"FG001","numSubjects":"74"},{"groupId":"FG002","numSubjects":"77"}],"type":"Eligible Population"},{"achievements":[{"groupId":"FG000","numSubjects":"77"},{"groupId":"FG001","numSubjects":"73"},{"groupId":"FG002","numSubjects":"76"}],"comment":"Eligible participants with adverse event data who started study treatment.","type":"Adverse Event Population"},{"achievements":[{"groupId":"FG000","numSubjects":"79"},{"groupId":"FG001","numSubjects":"74"},{"groupId":"FG002","numSubjects":"77"}],"comment":"Participants contributing data to results are considered to have completed the study.","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Registered patients who completed required baseline assessments were randomized. Of 238 registered patients, 230 were randomized."}